Lyra Therapeutics (LYRA) Net Cash Flow (2021 - 2025)
Lyra Therapeutics has reported Net Cash Flow over the past 5 years, most recently at -$6.2 million for Q4 2025.
- Quarterly results put Net Cash Flow at -$6.2 million for Q4 2025, down 136.73% from a year ago — trailing twelve months through Dec 2025 was -$29.3 million (down 255.77% YoY), and the annual figure for FY2025 was -$24.7 million, down 231.12%.
- Net Cash Flow for Q4 2025 was -$6.2 million at Lyra Therapeutics, up from -$7.7 million in the prior quarter.
- Over the last five years, Net Cash Flow for LYRA hit a ceiling of $88.0 million in Q2 2022 and a floor of -$77.0 million in Q4 2022.
- Median Net Cash Flow over the past 5 years was -$7.9 million (2024), compared with a mean of -$3.1 million.
- Peak annual rise in Net Cash Flow hit 2892.28% in 2022, while the deepest fall reached 522.04% in 2022.
- Lyra Therapeutics' Net Cash Flow stood at -$12.4 million in 2021, then crashed by 522.04% to -$77.0 million in 2022, then skyrocketed by 96.76% to -$2.5 million in 2023, then surged by 771.93% to $16.8 million in 2024, then tumbled by 136.73% to -$6.2 million in 2025.
- The last three reported values for Net Cash Flow were -$6.2 million (Q4 2025), -$7.7 million (Q3 2025), and -$6.6 million (Q2 2025) per Business Quant data.